Novartis AG
METHOD OF TREATING HIDRADENTITIS SUPPURATIVA WITH IL-17 ANTAGONISTS

Abstract:

The present disclosure relates to methods for treating Hidradenitis Suppurativa (HS) using IL-17 antagonists, e. g., secukinumab. Also disclosed herein are IL-17 antagonists, e.g., IL-17 antibodies, such as secukinumab, for treating HS patients, as well as medicaments, dosing regimens, pharmaceutical formulations, dosage forms, and kits for use in the disclosed uses and methods.